Diabetes Self-Management Blog

In a new joint position statement, the American Diabetes Association and European Association for the Study of Diabetes have recommended that physicians take an individualized, tailored approach when it comes to treating those with Type 2 diabetes. In the United States, an estimated 26 million people are living with this condition.

The new guidelines replace an algorithm, or step-by-step procedure, originally written by the two organizations in 2006 (and updated in 2008) to help advise health-care providers on how to choose between treatment options for people with Type 2. The earlier versions of the guidelines were created when less data was available on several widely used classes of diabetes drugs, such as DPP-4 inhibitors (Januvia [generic name sitagliptin], Onglyza [saxagliptin], and Tradjenta [linagliptin]) and GLP-1 agonists (Byetta [exenatide], Victoza [liraglutide], Bydureon [exenatide XR]), and recommended choosing from among insulin, sulfonylureas, thiazolidinediones, and Byetta if the first-line treatment options of lifestyle, diet, and metformin were not effective.

The new guidelines still recommend lifestyle interventions, including increased physical activity and improved diet, as the first step in treatment, and they still prescribe metformin as the first-line drug option. After that, however, rather than recommending specific classes of medicines, the statement discusses the various risks and benefits of the available drug classes and urges health-care providers to take this information into account to create customized treatment plans for their patients. For instance, information about the increased risk of bone fracture from medicines in the thiazolidinedione class (Actos [pioglitazone] and Avandia [rosiglitazone]) would be relevant when tailoring a plan for a postmenopausal woman.

According to Vivian Fonseca, president of the American Diabetes Association, “The wide range of pharmacological choices, along with conflicting data about some of those choices, and differences in how patients respond to medications, makes it difficult to prescribe a single treatment regimen based on an algorithm that is designed to work for everyone.”

The guidelines also suggest that blood glucose goals need to be individualized, and note that most people with Type 2 diabetes will ultimately need insulin therapy, either alone or in combination with other medicines, to maintain control of their diabetes.

In an e-mail to MedPage Today, David Nathan, MD, suggested that the new recommendations “provided relatively little guidance,” but added that this is not necessarily a bad thing, since the guidelines provide in-depth information about the various treatment options and leave the final choice about what’s most appropriate for an individual up to his doctor.

For more information, see the article “New Diabetes Guideline Urges Tailored Therapy” (free registration required) or download a copy of the guidelines from the journal Diabetes Care.

POST A COMMENT       
  

Comments
  1. gott in himmal. Holy Hannah - finally some intelligent comment besides the usual baffegab.

    Some key comments:

    Patience centered approach

    Evidence-based advice
    depends on the existence of primary
    source evidence.

    Any rise in glycemia is the net result of
    glucose influx exceeding glucose outflow
    from the plasma compartment. In the fasting
    state, hyperglycemia is directly related
    to increased hepatic glucose production.
    In the postprandial state, further glucose
    excursions result from the combination
    of insufficient suppression of this glucose
    output and defective insulin stimulation
    of glucose disposal in target tissues, mainly
    skeletal muscle. (Amazing - finally identifying Liver issues.)

    Metformin is most widely used first-line type 2 diabetes drug; its mechanism of action predominately involves reducing hepatic (liver) glucose production (54,55). No kidding! Finally an accurate answer.

    I am impressed with this report, its depth and comment. There has been far too much mis-information previously peddled. Also the patient centered/evidence based approach offers real chance for improvement in cures and care.

    Posted by jim snell |
  2. Metforman was the worst drug I have ever used! I have never been so sick in my whole life. It is about they realized all type 2 are not created equal!

    Posted by Betty Newby |
  3. Iam unclear how your dosage was set up.

    For me the huge dosages 2000 mg at a crack made me sick and pin in butt and did no good.

    It turns out due to research smaller doses 500 to 700 mg spread around clock do a better job than single huge doses that can make one sick and cause problems.

    your comments do not provide clue how you were taking/using.

    The best effects from metformin come from met up to strength in blood that causes liver to pull back release.

    Residuals and dosages above that simply hammer body in short run and only stick around the same 1 to 3 hours.

    And yes, there are those met is not ideal.

    Posted by jim snell |
  4. I have been taking the metformin 850 mg/2/day and have great results. My AIC was 14 and after 3 months of good diet, taking med correctly, I am now 6.2 and metformin reduced to 500mg. I am continuing my diet. I believe there may be cases where met doesn’t work, but I must be very lucky!!

    Posted by Karen |

Post a Comment

Note: All comments are moderated and there may be a delay in the publication of your comment. Please be on-topic and appropriate. Do not disclose personal information. Be respectful of other posters. Only post information that is correct and true to your knowledge. When referencing information that is not based on personal experience, please provide links to your sources. All commenters are considered to be nonmedical professionals unless explicitly stated otherwise. Promotion of your own or someone else's business or competing site is not allowed: Sharing links to sites that are relevant to the topic at hand is permitted, but advertising is not. Once submitted, comments cannot be modified or deleted by their authors. Comments that don't follow the guidelines above may be deleted without warning. Such actions are at the sole discretion of DiabetesSelfManagement.com. Comments are moderated Monday through Friday by the editors of DiabetesSelfManagement.com. The moderators are employees of Madavor Media, LLC., and do not report any conflicts of interest. A privacy policy setting forth our policies regarding the collection, use, and disclosure of certain information relating to you and your use of this Web site can be found here. For more information, please read our Terms and Conditions.


Type 2 Diabetes
Discovering I Had Type 2 Diabetes (10/17/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)
Long Hours at Low-Income Jobs Linked to Increased Diabetes Risk (10/02/14)
Metformin Study Currently Recruiting (08/19/14)

Diabetes News
FDA Approves Remote Glucose-Monitoring Technology (10/23/14)
Can Grapefruit Juice Prevent Weight Gain, Increase Insulin Sensitivity? (10/16/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)
Long Hours at Low-Income Jobs Linked to Increased Diabetes Risk (10/02/14)

Diane Fennell
FDA Approves Remote Glucose-Monitoring Technology (10/23/14)
Can Grapefruit Juice Prevent Weight Gain, Increase Insulin Sensitivity? (10/16/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)
Long Hours at Low-Income Jobs Linked to Increased Diabetes Risk (10/02/14)

 

 

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.